Navigation Links
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
Date:6/8/2008

Oral presentation at international lymphoma conference shows investigational regimen resulted in 82 percent overall survival and 78

percent progression-free survival rates in patients receiving

radioimmunotherapy Confirmatory phase III clinical trial is presently being conducted in this

patient population

LUGANO, Switzerland, June 9 /PRNewswire-FirstCall/ -- In an oral presentation today at the 10th International Conference on Malignant Lymphoma in Lugano, Switzerland, Paul A. Hamlin, M.D., of Memorial Sloan-Kettering Cancer Center, presented results of an investigator-sponsored trial of the investigational regimen consolidating rituximab-CHOP (R-CHOP) with 90Yttrium Ibritumomab Tiuxetan (Zevalin(R)) radioimmunotherapy in high risk, elderly patients with previously untreated high-intermediate and high risk diffuse large B-cell lymphoma (DLBCL). Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) markets Zevalin in the United States.

"In a high risk, elderly patient population with significant comorbidities, sequential R-CHOP followed by radioimmunotherapy resulted in excellent complete response and overall and progression-free survival rates," concluded Hamlin. "This approach is now the focus of an international phase III study."

"Improvement of relapse-free survival in these patients is an important unmet need since the outcome is poor for patients who relapse with this disease and who cannot tolerate intensive salvage therapy and stem cell transplantation," said Jack W. Singer, M.D., Chief Medical Officer at CTI. "The survival data from this study are highly encouraging compared to historical data and provide the rationale for a registration-directed randomized trial of Zevalin consolidation in higher risk patients with DLBCL."

Results of the Study

Historical studies provided as background in the presentation indicate that approximately 50 perc
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
2. Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
3. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
4. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
5. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
6. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
7. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
8. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
9. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
10. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
11. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 The Parenteral Drug ... harmonize global post-approval changes protocols. The ... the topic expressed by industry participants and regulatory authority ... this month in Washington, DC . ... on hand for the workshop. Attendees indicated openness to ...
(Date:9/19/2014)... 19, 2014 /PRNewswire-iReach/ -- "United States ... provides key market data on the ... The report provides value, in millions ... units) within market categories – Bronchoscopes, ... & Gastroscopes, Duodenoscopes, Laparoscopes, Hysteroscopes, Sinuscopes, ...
(Date:9/19/2014)... , Sept. 19, 2014  The board of ... declared a quarterly cash dividend of $0.42 per share.  ... 17, 2014 to stockholders of record at the close ... AbbVie AbbVie is a global, research-based biopharmaceutical company formed ... is to use its expertise, dedicated people and unique ...
Breaking Medicine Technology:PDA Launches Effort to Harmonize Global Post-Approval Changes Protocols 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5
... 31, 2011 Reportlinker.com announces that a ... its catalogue: Germany Surgical ... http://www.reportlinker.com/p0254518/Germany-Surgical-Equipment-Market-Outlook-to-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment Germany ... Summary GlobalData,s ...
... Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX ), an ... the third quarter ended September 30, 2011 and provided ... (FDA) approval of EXPAREL™ (bupivacaine liposome injectable suspension) and ... "With the broad postsurgical pain management label granted ...
Cached Medicine Technology:Germany Surgical Equipment Market Outlook to 2016 2Germany Surgical Equipment Market Outlook to 2016 3Germany Surgical Equipment Market Outlook to 2016 4Germany Surgical Equipment Market Outlook to 2016 5Germany Surgical Equipment Market Outlook to 2016 6Germany Surgical Equipment Market Outlook to 2016 7Germany Surgical Equipment Market Outlook to 2016 8Germany Surgical Equipment Market Outlook to 2016 9Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results 2Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results 3Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results 4Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results 5Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results 6Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results 7Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results 8Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results 9
(Date:9/20/2014)... Recently, Best Cheap Hosting USA (best-cheap-hosting-usa.com), a leading ... The new site provides the latest reviews on ... Here, people can find a lot of information ... has recommended some excellent web hosting suppliers for ... web hosting suppliers, InMotion ( http://www.best-cheap-hosting-usa.com/go/InMotion/ ), keeps ...
(Date:9/20/2014)... September 20, 2014 Plumbing construction ... out of 5, indicating a moderately favorable purchasing environment ... score reflects current and future pricing trends that will ... prices. Other factors that negatively affect buyer power are ... construction and the moderate switching costs. Buyers benefit, however, ...
(Date:9/20/2014)... 20, 2014 The Arizona Advanced ... is celebrating National Manufacturing Day by opening its doors ... processing and additive manufacturing labs will be offered between ... at MCC’s Southern and Dobson campus (1833 W. Southern ... Lot D. , The AzAMI at MCC was established ...
(Date:9/19/2014)... Nearly 780 Risperdal lawsuits are moving ... a meeting took place to discuss the next steps ... the court’s mass tort program. Attorneys for the plaintiffs ... at the Complex Litigation Center in Philadelphia’s City Hall ... The Risperdal lawsuits filed against Johnson & Johnson and ...
(Date:9/19/2014)... September 19, 2014 BearCom, a ... today detailed the key role played by instant, ... in the healthcare industry. , “In healthcare, ... care – and in emergency situations, can save ... life and death,” said Hugh Johnston, Product & ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 2Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 3Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 4
... CT angiography utilizing prospective electrocardiographic (ECG) gating produces ... dose when compared to retrospective ECG gating, according ... Roentgen Ray Society,s annual meeting. , The study ... the University Hospitals Case Medical Center, in Cleveland, ...
... TUESDAY, May 3 (HealthDay News) -- The U.S. Food ... are cracking down on manufacturers of over-the-counter products that ... The agencies jointly sent letters to companies including ... that their products are unproven and violate federal law, ...
... HealthDay Reporter , TUESDAY, May 3 (HealthDay News) -- ... lower their blood sugar level more effectively than just receiving ... review of data. After analyzing the results of ... for longer periods of time was better at bringing blood ...
... to play a key role in tumor survival, a research ... MD Anderson Cancer Center reports in an advance online publication ... suggests that the little-studied protein binds to the tumor-suppressing protein ... it for destruction by proteasomes, which degrade proteins and recycle ...
... HealthDay Reporter , TUESDAY, May 3 (HealthDay News) ... new U.S. study have TVs available for children to watch, ... Academy of Pediatrics, guidelines for television exposure in young kids. ... at daycares may be missing out on the kind of ...
... Cell biologist Daniel Gottschling, Ph.D., a member of the ... been elected to membership in the National Academy of Sciences. ... that can be accorded a U.S. scientist or engineer. "I ... peers," said Gottschling, who will be inducted into the Academy ...
Cached Medicine News:Health News:Low-dose chest CT effective in reducing radiation for evaluation of cardiothoracic surgery patients 2Health News:U.S. Officials Take Aim at Questionable STD Products 2Health News:Structured Exercise Programs Help Lower Blood Sugar, Study Finds 2Health News:Structured Exercise Programs Help Lower Blood Sugar, Study Finds 3Health News:Protein identified as enemy of vital tumor suppressor PTEN 2Health News:TVs Common in Daycare Centers, Flouting Guidelines 2Health News:TVs Common in Daycare Centers, Flouting Guidelines 3Health News:Cell biologist Daniel Gottschling elected to National Academy of Sciences 2
... immersion objective has a higher numerical aperture ... media helps eliminate surface,reflections and provides an ... excellent objective for fluorescence, brightfield and DIC ... correction collar that allows it to be ...
... is a very versatile light source ... variety of applications anytime a Zeiss ... illumination with optimum protection without heating ... most economical cold-light source that completes ...
... a complete line of ... halogen light sources that ... A solid-state dimmer provides ... our exclusive Modulamp assembly ...
Standard 20x long working distance objectives for greater magnifications of your microtools....
Medicine Products: